Cultural adaptation, validation and development of a Spanish brief version of the diabetes fear of injecting and self-testing questionnaire;Adaptación cultural, validación y desarrollo de un cuestionario abreviado sobre el miedo a la inyección y al autoanálisis de glucosa para pacientes diabéticos

Endocrinologia y Nutricion

Volumn 55, Issue 8, 2008, Pages 326-332

  Baillo, Pilar ^a   Laporta, Felix ^b   Martorell, Joan ^a   González, Paloma ^c   Rebollo, Pablo ^d   Moris, Joaquín ^d   Rejas, Javier ^c   Díaz Cerezo, Silvia ^c  

^a Centro de Atencion Primaria de Ponts   (Spain)

^b Centro de Salud La Roda   (Spain)

^c PFIZER INC   (United States)

^d BAP Health Outcomes   (Spain)

Author keywords

Diabetes; Fear; Glycemic control; Injection; Insulin; Questionnaire

Indexed keywords

INSULIN;

ADULT; AGED; ANXIETY; ARTICLE; CONSTRUCT VALIDITY; CONTROLLED STUDY; CULTURAL FACTOR; FEAR; FEMALE; GLYCEMIC CONTROL; HUMAN; INJECTION PAIN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; QUESTIONNAIRE; SELF EVALUATION; SPAIN;

EID: 55449114742     PISSN: 15750922     EISSN: 15792021     Source Type: Journal    
DOI: 10.1016/S1575-0922(08)72792-X     Document Type: Article

References (26)

1. Kolko DJ, Milan MA. Misconception correction through reading in the treatment of a self-injection phobia. J Behav Ther Exp Psychiatry. 1980;11:273-6.
2. Metsch J, Tilill H, Koebberling J, Sartory G. On the relations among psychological distress, diabetes-related health behaviour and level of glycosylated hemoglobin in type I diabetes. Int J Behav Med. 1995;2:104-17.
3. Berlin I, Bisserbe JC, Eiber R, Balssa N, Sachon C, Bosquet F, et al. Phobic symptoms, particularly the fear of blood and injury, are associated with poor glycemic control in type I diabetic adults. Diabetes Care. 1997;20:176-8.
4. Zambanini A, Newson RB, Maisey M, Feher MD. Injection related anxiety in insulin-treated diabetes. Diabetes Res Clin Pract. 1999;46:239-46.
5. Snoek FJ, Mollema ED, Heine RJ, Bouter LM, Van der Ploeg HM. Development and validation of the diabetes fear of injecting and self-testing questionnaire (D-FISQ): first findings. Diab Med. 1997;14:871-6.
6. Mollema ED, Snoek FJ, Pouwer F, Heine RJ, Van der Ploeg HM. Diabetes Fear of Injecting and Self-testing questionnaire (D-FISQ). A psychometric evaluation. Diabetes Care. 2000;23:765-9.
7. Mollema ED, Snoek FJ, Heine RJ, Van der Ploeg HM. Phobia of self-injecting and self-testing in insulin- treated diabetes patients: opportunities for screening. Diabet Med. 2001;18:671-4.
8. Mollema ED, Snoek FJ, Ader HJ, Heine RJ, Van der Ploeg HM. Insulin-treated diabetes patients with fear of self-injecting or fear of self-testing: psychological comorbidity and general well-being. J Psychosom Res. 2001;51:665-72.
9. Wagner J, Malchoff C, Abbott G. Invasiveness as a barrier to self-monitoring of blood glucose in diabetes. Diabetes Technol Ther. 2005;7:612-9.
10. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes. 2002;Suppl 3:18-24.
11. Pop Bogatean M, Hâncu N. People with type 2 diabetes facing the reality of starting insulin therapy: factors involved in psychological insulin resistance. Pract Diabetes Int. 2004;21:247-52.
12. Hunt LM, Valenzuela MA, Pugh JA. NIDDM patients' fears and hopes about insulin therapy. The basis of patients reluctance. Diabetes Care. 1997;20:292-8.
13. Polonsky WH, Jackson RA. What's so tough about taking insulin? Addressing the problem of phychological insulin resistance in type 2 diabetes. Clin Diabetes. 2004;22:147-50.
14. Leslie CA, Satin-Rapaport W, Matheson D, Stone R, Enfield G. Psychological insulin resistance: a missed diagnosis? Diabetes Spectrum. 1994;7:52-7.
15. Snoek FJ. Breaking the barriers to optimal glycaemic control - what physician need to know from patientt's perspectives. Int J Clin Pract Suppl. 2002;129:80-4.
16. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-86.
17. Straton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-12.
18. Mata M, Roset M, Badia X, Antoñanzas F, Rabel J. Impacto de la diabetes mellitus tipo 2 en la calidad de vida de los pacientes tratados en las consultas de atención primaria en España. Aten Primaria. 2003;31:493-9.
19. González P, Faure E, Del Castillo A, por el grupo de trabajo para el Estudio del Coste de la Diabetes. El coste de la diabetes mellitus en España. Una revisión sistemática de la literatura. Med Clin (Barc). 2005;127:776-84.
20. Ballesta MJ, Carral F, Olveira G, Girón JA, Aguilar M. Costes asociados a la diabetes tipo 1. Rev Clin Esp. 2005;205:523-7.
21. Aguilar M, Ballesta M, Carral F y Grupo de Diabetes de la SAEN. Costes indirectos de la diabetes mellitus tipo 2 (DM2). Endocrinol Nutr. 2002;49:59-69.
22. Harsch IA. Inhaled insulins: their potential in the treatment of diabetes mellitus. Treat Endocrinol. 2005;4:131-8.
23. Freemantle N, Blonde L, Duhot D, Hompesch M, Eggertsen R, Hobbs FDR, et al. Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes. Diabetes Care. 2005;28:427-8.
24. a ed. Madrid: TEA; 1986.
25. Grupo de trabajo Nuevas Tecnologías de la Sociedad Española de Diabetes. Nuevas tecnologías en el seguimiento y control del paciente diabético. Madrid: Sociedad Española de Diabetes; 2007.
26. Costa PT, McCrae RR. Hypochondriasis, neuroticism, and aging. When are somatic complaints unfounded? Am Psychol. 1985;40:19-28.